Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of telmisartan + levoamlodipine versus amlodipine in primary hypertension uncontrolled after 4 weeks of amlodipine monotherapy
CTR20242170Phase 3Active
- Sponsor
- Jiangxi Shimei Pharmaceutical
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of telmisartan, Levamlodipine in essential hypertension, sponsored by Jiangxi Shimei Pharmaceutical. Started Aug 2024; status: active.
02
Drugs
telmisartanLevamlodipine
03
Conditions
essential hypertension
Beyond the preview
Go deeper on CTR20242170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242170.